Integra cuts 2026 outlook as flood recovery extends into next year
The medical-device maker lowers sales and adjusted earnings guidance while separately seeking a $600 million refinancing. Preliminary results and financing terms remain unfinished.
Universal file
SEC-verified company · Nasdaq · IART
1 sourced report in this file.
Verified identity
The identity and ticker come from the SEC’s official company ticker mapping. Market and editorial coverage are not inferred from that record.
Market price
Latest quoteOpens Google
Coverage digest
TickerGrove has published 1 sourced report on INTEGRA LIFESCIENCES HOLDINGS CORP since Oct 2, 2026. The latest, published Oct 2, 2026, is “Integra cuts 2026 outlook as flood recovery extends into next year”
The medical-device maker lowers sales and adjusted earnings guidance while separately seeking a $600 million refinancing. Preliminary results and financing terms remain unfinished.
The report's verified figures include Integra full-year reported revenue guidance U.S. dollars; management forecast of $1.634 billion–$1.654 billion (Full year 2026; outlook reduced October 2, 2026) and Proposed senior secured Term Loan B U.S. dollars; proposed principal amount of $600 million (Launched October 2, 2026; seven-year proposed tenor; not completed financing).
TickerGrove coverage
Research foundation
Company analysis
Revenue is the top-line amount recognized from a company’s activities under its accounting policy.
Company analysis
This guide covers three statements: the income statement, the balance sheet and the cash-flow statement.
Investing basics
A stock is an ownership interest in one company.